Scholar Rock Holding (FRA:2QK) Scaled Net Operating Assets: 0.00 (As of Mar. 2026)


FRA:2QK Scholar Rock Holding Corp FRA:2QK
28 GF Score
Price €47.69
! 5 Warning Signs
View Full Analysis

What is Scholar Rock Holding Scaled Net Operating Assets?

Scholar Rock Holding FRA:2QK +3.45% 28 Scaled Net Operating Assets is 0.00 as of Mar. 2026. GuruFocus rates FRA:2QK with a GF Score™ of 28/100. The stock has 5 warning signs investors should review.

Scaled Net Operating Assets (SNOA) is calculated as the difference between operating assets and operating liabilities, scaled by lagged total assets.

Scholar Rock Holding's operating assets for the quarter that ended in Mar. 2026 was €47.84 Mil. Scholar Rock Holding's operating liabilities for the quarter that ended in Mar. 2026 was €46.34 Mil. Scholar Rock Holding's Total Assets for the quarter that ended in Dec. 2025 was €345.25 Mil. Therefore, Scholar Rock Holding's scaled net operating assets (SNOA) for the quarter that ended in Mar. 2026 was 0.00.

Scholar Rock Holding Scaled Net Operating Assets Historical Data

* Premium members only.

The historical data trend for Scholar Rock Holding's Scaled Net Operating Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Scholar Rock Holding Scaled Net Operating Assets Chart

Scholar Rock Holding Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Scaled Net Operating Assets
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.01 0.05 0.02 -0.01 -0.03

Scholar Rock Holding Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Scaled Net Operating Assets Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.02 0.00 -0.04 -0.03 0.00

FRA:2QK vs COGT, CGON, PTCT: Scaled Net Operating Assets Comparison

For the Biotechnology subindustry, Scholar Rock Holding's Scaled Net Operating Assets, along with its competitors' market caps and Scaled Net Operating Assets data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Scholar Rock Holding Scaled Net Operating Assets vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Scholar Rock Holding's Scaled Net Operating Assets distribution charts can be found below:

* The bar in red indicates where Scholar Rock Holding's Scaled Net Operating Assets falls into.


FRA:2QK
28GF Score
Scholar Rock Holding Corp FRA:2QK
Scaled Net Operating Assets is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Scholar Rock Holding Scaled Net Operating Assets Calculation

Scaled Net Operating Assets (SNOA) is calculated as the difference between operating assets and operating liabilities, scaled by lagged total assets.

Scholar Rock Holding's Scaled Net Operating Assets (SNOA) for the fiscal year that ended in Dec. 2025 is calculated as

Scaled Net Operating Assets (SNOA)(A: Dec. 2025 )
=(Operating Assets (A: Dec. 2025 )-Operating Liabilities (A: Dec. 2025 ))/Total Assets (A: Dec. 2024 )
=(31.349-42.588)/453.551
=-0.02

where

Operating Assets(A: Dec. 2025 )
=Total Assets - Cash, Cash Equivalents, Marketable Securities
=345.248 - 313.899
=31.349

Operating Liabilities(A: Dec. 2025 )
=Total Liabilities - Long-Term Debt & Capital Lease Obligation - Short-Term Debt & Capital Lease Obligation
=135.602 - 88.274 - 4.74
=42.588

Scholar Rock Holding's Scaled Net Operating Assets (SNOA) for the quarter that ended in Mar. 2026 is calculated as

Scaled Net Operating Assets (SNOA)(Q: Mar. 2026 )
=(Operating Assets (Q: Mar. 2026 )-Operating Liabilities (Q: Mar. 2026 ))/Total Assets (Q: Dec. 2025 )
=(47.843-46.335)/345.248
=0.00

where

Operating Assets(Q: Mar. 2026 )
=Total Assets - Cash, Cash Equivalents, Marketable Securities
=462.995 - 415.152
=47.843

Operating Liabilities(Q: Mar. 2026 )
=Total Liabilities - Long-Term Debt & Capital Lease Obligation - Short-Term Debt & Capital Lease Obligation
=224.243 - 172.652 - 5.256
=46.335

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Scaled Net Operating Assets of 0.00 mean?
Scholar Rock Holding (FRA:2QK) has a Scaled Net Operating Assets of 0.00 as of Mar. 2026. Scaled net operating assets equals current-period operating assets less operating liabilities less prior-period total assets. View historical data on Scholar Rock Holding and its competitors.
Is Scholar Rock Holding's Scaled Net Operating Assets too high?
Scholar Rock Holding's current Scaled Net Operating Assets is 0.00. Overall, Scholar Rock Holding has a GF Score™ of 28/100, reflecting its overall financial health beyond just this single metric.
How does Scholar Rock Holding's Scaled Net Operating Assets compare to COGT and CGON?
Scholar Rock Holding's Scaled Net Operating Assets of 0.00 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Scaled Net Operating Assets for a Biotechnology company?
A good Scaled Net Operating Assets depends on the Biotechnology industry context. However, Scaled Net Operating Assets should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Scaled Net Operating Assets mean?
A high Scaled Net Operating Assets can signal that a stock is expensive relative to its fundamentals. Scaled net operating assets equals current-period operating assets less operating liabilities less prior-period total assets. View historical data on Scholar Rock Holding and its competitors. Scholar Rock Holding's current Scaled Net Operating Assets is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Scholar Rock Holding stock overvalued right now?
Scholar Rock Holding (FRA:2QK) has a current Scaled Net Operating Assets of 0.00. The current Scaled Net Operating Assets is 0.00. Scholar Rock Holding's overall GF Score™ is 28/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Scaled Net Operating Assets calculated?
Scaled Net Operating Assets is calculated from a company's financial statements. For Scholar Rock Holding (FRA:2QK), the current Scaled Net Operating Assets is 0.00 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Scholar Rock Holding Business Description

Other Exchanges SRRK:USA2QK:Germany
Address 301 Binney Street, 3rd Floor, Cambridge, MA, USA, 02142
Scholar Rock Holding Corp is a biopharmaceutical company focused on improving the lives of children and adults with Spinal Muscular Atrophy and other rare, severe, and debilitating neuromuscular diseases. Its pipeline candidates include apitegromab and a subcutaneous formulation of apitegromab. The clinical-stage pipeline also includes SRK-439, an investigational subcutaneously administered fully human anti-pro/latent myostatin antibody with high inhibitory potency and selectivity toward myostatin, being developed for the treatment of rare neuromuscular diseases. The company also maintains early-stage programs focused on therapies for rare, severe, and debilitating neuromuscular diseases.
28GF Score

Get the complete analysis for FRA:2QK

Scaled Net Operating Assets is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€47.69
Price